The mechanisms that drive responses to PD-1-blocking immunotherapy in some but not all patients have been puzzling. A new study suggests that the balance of PD-1 expression levels between CD8+ T cells and Treg cells might provide an answer.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Blocking CXCR4+ CD4+ T cells reprograms Treg-mediated immunosuppression via modulating the Rho-GTPase/NF-κB signaling axis
Genome Medicine Open Access 04 August 2025
-
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics
Cell Death & Disease Open Access 01 April 2025
-
Regulatory T cells in immune checkpoint blockade antitumor therapy
Molecular Cancer Open Access 08 November 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Debbie Maizels/Springer Nature
References
Kumagai, S. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-0769-3 (2020).
Miyara, M. et al. Immunity 30, 899–911 (2009).
Wing, J. B., Tanaka, A. & Sakaguchi, S. Immunity 50, 302–316 (2019).
Hsieh, C.-S. et al. Immunity 21, 267–277 (2004).
Fife, B. T. et al. J. Exp. Med. 203, 2737–2747 (2006).
Zhang, B., Chikuma, S., Hori, S., Fagarasan, S. & Honjo, T. Proc. Natl Acad. Sci. USA 113, 8490–8495 (2016).
Francisco, L. M. et al. J. Exp. Med. 206, 3015–3029 (2009).
Patsoukis, N. et al. Nat. Commun. 6, 6692 (2015).
Shi, L. Z. et al. J. Exp. Med. 208, 1367–1376 (2011).
Haxhinasto, S., Mathis, D. & Benoist, C. J. Exp. Med. 205, 565–574 (2008).
Delgoffe, G. M. et al. Immunity 30, 832–844 (2009).
Ali, K. et al. Nature 510, 407–411 (2014).
Acknowledgements
This work was supported by the National Institutes of Health awards RO1CA212605, RO1CA238263 and RO1CA229784 (V.A.B.).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
V.A.B. has patents on the PD-1 pathway licensed by Bristol-Myers Squibb, Roche, Merck, EMD-Serono, Boehringer Ingelheim, AstraZeneca, Novartis and Dako. The authors declare no other competing interests.
Rights and permissions
About this article
Cite this article
Aksoylar, HI., Boussiotis, V.A. PD-1+ Treg cells: a foe in cancer immunotherapy?. Nat Immunol 21, 1311–1312 (2020). https://doi.org/10.1038/s41590-020-0801-7
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41590-020-0801-7
This article is cited by
-
Blocking CXCR4+ CD4+ T cells reprograms Treg-mediated immunosuppression via modulating the Rho-GTPase/NF-κB signaling axis
Genome Medicine (2025)
-
Immune evasion mechanisms in early-stage I high-grade serous ovarian carcinoma: insights into regulatory T cell dynamics
Cell Death & Disease (2025)
-
Regulatory T cells in the tumour microenvironment
Nature Reviews Cancer (2025)
-
Regulatory T cells in immune checkpoint blockade antitumor therapy
Molecular Cancer (2024)
-
Hypothesis of a CD137/Eomes activating axis for effector T cells in HPV oropharyngeal cancers
Molecular Medicine (2024)
